Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A50325 | 35433752 | Front Med (Lausanne) | Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A50328 | 35431924 | Front Pharmacol | NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer. | 2022 | Details |
| A50334 | 35430025 | J Clin Lipidol | JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. | 2022 | Details |
| A50335 | 35429980 | Cardiovasc Diabetol | The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. | 2022 | Details |
| A50338 | 35429042 | FASEB J | Serpina3c deficiency induced necroptosis promotes non-alcoholic fatty liver disease through β-catenin/Foxo1/TLR4 signaling. | 2022 | Details |
| A50345 | 35427375 | PLoS One | Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. | 2022 | Details |
| A50351 | 35421583 | Clin Gastroenterol Hepatol | Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. | 2022 | Details |
| A50355 | 35420707 | Chem Asian J | Advances in Optical Imaging of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50357 | 35419698 | Obes Surg | Reversal of NAFLD After VSG Is Independent of Weight-Loss but RYGB Offers More Efficacy When Maintained on a High-Fat Diet. | 2022 | Details |
| A50361 | 35417923 | Hum Mol Genet | Role of non-coding RNAs on liver metabolism and NAFLD pathogenesis. | 2022 | Details |
| A50364 | 35417420 | Anesth Analg | Liver Fibrosis Marker and Postoperative Mortality in Patients Without Overt Liver Disease. | 2022 | Details |
| A50365 | 35416741 | Scand J Clin Lab Invest | Nonalcoholic fatty liver disease and its prognosis associates with shorter leucocyte telomeres in a 21-year follow-up study. | 2022 | Details |
| A50369 | 35413987 | BMC Health Serv Res | Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes. | 2022 | Details |
| A50372 | 35413401 | Biochim Biophys Acta Mol Basis Dis | The Annexin A2-Notch regulatory loop in hepatocytes promotes liver fibrosis in NAFLD by increasing osteopontin expression. | 2022 | Details |
| A50374 | 35412487 | Eur J Gastroenterol Hepatol | Left ventricular strain predicts subclinical atherosclerosis in nonadvanced nonalcoholic fatty liver disease patients. | 2022 | Details |
| A50375 | 35412485 | Eur J Gastroenterol Hepatol | An elevated FIB-4 score is not associated with cardiovascular events: a longitudinal analysis from 137 842 patients with and without chronic liver disease. | 2022 | Details |
| A50379 | 35411570 | Hepatol Commun | Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV. | 2022 | Details |
| A50386 | 35409028 | Int J Mol Sci | SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50390 | 35407364 | J Clin Med | Improvement of Type 2 Diabetes Mellitus and Attenuation of NAFLD Are Associated with the Success of Obesity Therapy. | 2022 | Details |
| A50396 | 35405948 | Nutrients | Do MAFLD Patients with Harmful Alcohol Consumption Have a Different Dietary Intake? | 2022 | Details |
| A50397 | 35405942 | Nutrients | Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis. | 2022 | Details |
| A50398 | 35405176 | J Hepatol | Rare ATG7 genetic variants predispose patients to severe fatty liver disease. | 2022 | Details |
| A50407 | 35402722 | Clin Exp Hepatol | Evaluation of thyroid function and thyroid autoimmune disease in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A50421 | 35397765 | Infect Dis Ther | The Role of Metabolic Factors and Steatosis in Treatment-Naïve Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase. | 2022 | Details |
| A50427 | 35396116 | Endocrinol Diabetes Nutr (Engl Ed) | Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity. | 2022 | Details |
| A50435 | 35393310 | BMJ Open | Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV. | 2022 | Details |
| A50441 | 35391713 | Arch Pharm Res | Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. | 2022 | Details |
| A50443 | 35389416 | Food Funct | Structural characterization and preventive effect on non-alcoholic fatty liver disease of oligosaccharides from Bletilla striata. | 2022 | Details |
| A50447 | 35387749 | Eur J Intern Med | Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. | 2022 | Details |
| A50449 | 35386158 | Cureus | Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome. | 2022 | Details |
| A50450 | 35386040 | Obes Surg | Bariatric Surgery Improves Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. | 2022 | Details |
| A50452 | 35385510 | PLoS One | Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. | 2022 | Details |
| A50455 | 35384259 | Liver Int | An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution. | 2022 | Details |
| A50456 | 35384023 | Clin Endocrinol (Oxf) | Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients with pituitary stalk interruption syndrome. | 2022 | Details |
| A50464 | 35380992 | J Clin Invest | Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. | 2022 | Details |
| A50468 | 35378329 | Mol Metab | Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function. | 2022 | Details |
| A50474 | 35373500 | Liver Int | Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia. | 2022 | Details |
| A50481 | 35369116 | Can J Gastroenterol Hepatol | Liver Fibrosis Scores and Hospitalization, Mechanical Ventilation, Severity, and Death in Patients with COVID-19: A Systematic Review and Dose-Response Meta-Analysis. | 2022 | Details |
| A50484 | 35368120 | J Gastroenterol Hepatol | Magnetic resonance imaging metrics and the predictability of adverse outcomes in on-treatment Asian chronic hepatitis B. | 2022 | Details |
| A50493 | 35365931 | Hepatol Commun | Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. | 2022 | Details |
| A50494 | 35365570 | Gut | NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. | 2022 | Details |
| A50495 | 35365418 | Hepatobiliary Pancreat Dis Int | Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A50499 | 35363908 | Hepatology | Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? | 2022 | Details |
| A50500 | 35363906 | Hepatology | An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project. | 2022 | Details |
| A50502 | 35362158 | J Gastroenterol Hepatol | Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems. | 2022 | Details |
| A50505 | 35360054 | Front Endocrinol (Lausanne) | Relationship Between Non-Alcoholic Fatty Liver Disease and Degree of Hepatic Steatosis and Bone Mineral Density. | 2022 | Details |
| A50523 | 35354619 | BMJ Open | Validation of type 2 diabetes subgroups by simple clinical parameters: a retrospective cohort study of NHANES data from 1999 to 2014. | 2022 | Details |
| A50524 | 35354614 | BMJ Open | Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. | 2022 | Details |
| A50529 | 35352691 | Eur J Gastroenterol Hepatol | Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study). | 2022 | Details |
| A50530 | 35352460 | Hepatol Res | Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. | 2022 | Details |
| A50531 | 35351975 | Sci Rep | In vitro ballooned hepatocytes can be produced by primary human hepatocytes and hepatic stellate cell sheets. | 2022 | Details |
| A50534 | 35350750 | Front Pharmacol | The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment. | 2022 | Details |
| A50535 | 35349726 | Hepatology | PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features. | 2022 | Details |
| A50536 | 35349482 | J Clin Invest | Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model. | 2022 | Details |
| A50537 | 35349415 | Clin Exp Rheumatol | Improvement in hepatic fibrosis estimated by Fibrosis-4 index in pegloticase treated chronic refractory gout patients. | 2022 | Details |
| A50547 | 35345491 | Front Cardiovasc Med | Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis. | 2022 | Details |
| A50550 | 35344814 | Int Immunopharmacol | Mitigation of liver fibrosis via hepatic stellate cells mitochondrial apoptosis induced by metformin. | 2022 | Details |
| A50554 | 35343663 | Minerva Gastroenterol (Torino) | Associations between muscle mass, strength, and performance and non-alcoholic fatty liver disease. | 2022 | Details |
| A50558 | 35341737 | J Lipid Res | Maternal obesogenic diet enhances cholestatic liver disease in offspring. | 2022 | Details |
| A50559 | 35340212 | Oxid Med Cell Longev | No Evidence for a Causal Link between Serum Uric Acid and Nonalcoholic Fatty Liver Disease from the Dongfeng-Tongji Cohort Study. | 2022 | Details |
| A50562 | 35339664 | Diabetes Metab | The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. | 2022 | Details |
| A50565 | 35338555 | Liver Int | Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea. | 2022 | Details |
| A50568 | 35338048 | BMJ Open Gastroenterol | Metabolic dysfunction-related liver disease as a risk factor for cancer. | 2022 | Details |
| A50573 | 35334881 | Nutrients | The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004. | 2022 | Details |
| A50574 | 35334864 | Nutrients | High Compliance to Mediterranean Diet Associates with Lower Platelet Activation and Liver Collagen Deposition in Patients with Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50575 | 35334792 | Nutrients | Exosomal FZD-7 Expression Is Modulated by Different Lifestyle Interventions in Patients with NAFLD. | 2022 | Details |
| A50578 | 35334125 | Hepatology | Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. | 2022 | Details |
| A50582 | 35333295 | Alcohol Alcohol | Alcohol Consumption: Medical Implications, the Liver and Beyond. | 2022 | Details |
| A50584 | 35332833 | Postgrad Med | Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population. | 2022 | Details |
| A50585 | 35332569 | Hepatology | Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. | 2022 | Details |
| A50586 | 35332431 | Intern Emerg Med | Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity. | 2022 | Details |
| A50588 | 35332111 | J Obes Metab Syndr | Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50589 | 35331917 | Mol Cell Proteomics | Imaging Mass Spectrometry Reveals Alterations in N-Linked Glycosylation That Are Associated With Histopathological Changes in Nonalcoholic Steatohepatitis in Mouse and Human. | 2022 | Details |
| A50591 | 35331317 | Diabetol Metab Syndr | NAFLD in normal weight individuals. | 2022 | Details |
| A50597 | 35328778 | Int J Mol Sci | Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy. | 2022 | Details |
| A50600 | 35328564 | Int J Mol Sci | A Novel Sprague-Dawley Rat Model Presents Improved NASH/NAFLD Symptoms with PEG Coated Vitexin Liposomes. | 2022 | Details |
| A50601 | 35328527 | Int J Mol Sci | SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. | 2022 | Details |
| A50603 | 35328352 | Int J Mol Sci | Beneficial Effects of Dietary Nitrite on a Model of Nonalcoholic Steatohepatitis Induced by High-Fat/High-Cholesterol Diets in SHRSP5/Dmcr Rats: A Preliminary Study. | 2022 | Details |
| A50605 | 35327746 | Children (Basel) | Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50607 | 35327501 | Biomedicines | Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. | 2022 | Details |
| A50609 | 35327352 | Biomedicines | Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role. | 2022 | Details |
| A50610 | 35327326 | Biomedicines | The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. | 2022 | Details |
| A50613 | 35325622 | Lancet Gastroenterol Hepatol | Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. | 2022 | Details |
| A50617 | 35325295 | J Gastroenterol | Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD. | 2022 | Details |
| A50622 | 35323681 | Metabolites | Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH. | 2022 | Details |
| A50629 | 35321955 | Gut Liver | Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. | 2022 | Details |
| A50636 | 35319156 | Liver Int | Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study. | 2022 | Details |
| A50639 | 35318571 | Indian J Gastroenterol | Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A50640 | 35318425 | Sci Rep | Non-invasive tests for liver fibrosis assessment in patients with chronic liver diseases: a prospective study. | 2022 | Details |
| A50643 | 35317606 | Thyroid | Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis. | 2022 | Details |
| A50644 | 35317426 | World J Gastroenterol | Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. | 2022 | Details |
| A50646 | 35317178 | World J Hepatol | Rodent models and metabolomics in non-alcoholic fatty liver disease: What can we learn? | 2022 | Details |
| A50647 | 35317172 | World J Hepatol | Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? | 2022 | Details |
| A50651 | 35314476 | BMJ Open | Role of age, gender and ethnicity in the association between visceral adiposity index and non-alcoholic fatty liver disease among US adults (NHANES 2003-2018): cross-sectional study. | 2022 | Details |
| A50654 | 35312970 | Diabetes Ther | Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study. | 2022 | Details |
| A50655 | 35312295 | ACS Nano | Heterogeneous Iron Oxide/Dysprosium Oxide Nanoparticles Target Liver for Precise Magnetic Resonance Imaging of Liver Fibrosis. | 2022 | Details |
| A50656 | 35312185 | Hepatol Commun | Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease. | 2022 | Details |
| A50662 | 35309311 | Front Immunol | Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy. | 2022 | Details |
| A50663 | 35308892 | Metabol Open | Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives. | 2022 | Details |
| A50667 | 35308229 | Front Pharmacol | Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies. | 2022 | Details |